RedHill Biopharma (RDHL) Interest Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Interest Expenses data on file, last reported at $1.9 million in Q2 2023.

• On a quarterly basis, Interest Expenses fell 54.3% year-over-year to $1.9 million in Q2 2023; TTM through Dec 2024 was $1.9 million, a 60.11% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 3.7% from the prior year.
• Interest Expenses for Q2 2023 stood at $1.9 million, up from $421000.0 in the prior quarter.
• Over the last five years, Interest Expenses for RDHL reached as high as $31.8 million in Q3 2022 and fell as low as -$7.6 million in Q4 2021.
• Historically, Interest Expenses has averaged $3.2 million across 5 years, with a median of $2.2 million in 2022.
• On a YoY basis, Interest Expenses climbed as much as 2148.54% in 2020 and fell as far as 1262.03% in 2020.
• Year by year, Interest Expenses stood at $187000.0 in 2019, then slumped by 1262.03% to -$2.2 million in 2020, then tumbled by 250.12% to -$7.6 million in 2021, then jumped by 132.61% to $2.5 million in 2022, then declined by 22.37% to $1.9 million in 2023.
• Per Business Quant data, the three most recent Interest Expenses figures were $1.9 million in Q2 2023, $421000.0 in Q1 2023, and $2.5 million in Q4 2022.